Assess bleeding risk with HAS-BLED and assess stroke risk with CHA 2DS2-VASc in patients with atrial fibrillation

Hypertension Research

Volumn 37, Issue 7, 2014, Pages 699-700

  Lau, Yee C ^a   Lip, Gregory Y ^a   Gallego, Pilar ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; WARFARIN; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CLINICAL ASSESSMENT TOOL; COMPARATIVE EFFECTIVENESS; HAS BLED SCORE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LETTER; LOW RISK PATIENT; PREDICTIVE VALUE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCORING SYSTEM; THROMBOEMBOLISM; BRAIN ISCHEMIA; COMPLICATION; FEMALE; MALE; STROKE;

ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; STROKE;

EID: 84904883120     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.63     Document Type: Letter

References (12)

1. Toyoda K, Yasaka M, Uchiyama S, Iwade K, Koretsune Y, Nagata K, Sakamoto T, Nagao T, Yamamoto M, Gotoh J, Takahashi JC, Minematsu K and The Bleeding with Antithrombotic Therapy Study Group. CHADS2 and CHA2DS2-VASc scores as bleeding risk indices for patients with atrial fibrillation: The Bleeding with Antithrombotic Therapy Study. Hypertens Res 2014; 37: 463-466.
2. Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thromb Haemost 2013; 110: 1074-1079.
3. Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY. The HAS-BLED score has better prediction accuracy for major bleeding than the CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013; 62: 2199-2204.
4. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
5. Gallego P, Roldán V, Torregrosa JM, Gá lvez J, Valdés M, Vicente V, Marín F, Lip GYH. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5: 312-318.
6. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
7. Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013; 109: 328-336.
8. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P. European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
9. Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
10. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT2R2 score. Chest 2013; 144: 1555-1563.
11. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
12. Lip GY, Lane DA, Buller H, Apostolakis S. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: The AMADEUS study. Chest 2013; 144: 1839-1847.